查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988475

內分泌藥物市場：2026年至2032年全球市場預測（依藥物類別、治療領域、給藥途徑、病患年齡層及分銷管道分類）

Endocrinology Drugs Market by Drug Class, Therapy Area, Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，內分泌藥物市場價值將達到 654.3 億美元，到 2026 年將成長至 701.2 億美元，到 2032 年將達到 1,097.8 億美元，複合年成長率為 7.67%。

主要市場統計數據
基準年 2025 654.3億美元
預計年份：2026年 701.2億美元
預測年份 2032 1097.8億美元
複合年成長率 (%) 7.67%

權威概述了治療方法創新、監管變化和患者期望如何改變內分泌領域的藥物策略和護理路徑。

許多疾病的慢性特徵、生物製藥和小分子藥物的持續創新，以及患者對治療便利性和療效的期望不斷變化，使得內分泌治療成為現代醫療保健的核心。在臨床和商業領域，相關人員越來越重視那些能夠改善代謝控制、降低併發症發生率並透過改進製劑和給藥系統來提高患者長期用藥依從性的干涉措施。因此，對於必須在臨床療效和實際應用挑戰之間取得平衡的臨床醫生、商業領袖和政策顧問而言，對治療創新、監管趨勢和患者可及性趨勢進行全面研究至關重要。

生物製藥、給藥系統、數位療法和法規結構的創新如何共同重新定義整個內分泌治療領域的競爭策略。

在內分泌學領域，一場變革正在發生，生物製藥、胜肽工程和遞送技術的進步推動了這項變革，提高了療效並提升了患者的便利性。新型GLP-1受體促效劑和長效胰島素類似物正在引領新的治療標準，而藥物科學的進步則使得減少給藥頻率和拓展給藥途徑成為可能。同時，數位健康平台和遠端監測工具正與治療方法相結合，以支持藥物依從性、劑量調整和個人化護理計劃，從而影響臨床試驗設計和上市後證據的生成。

2025年關稅對醫藥生態系統內供應鏈、籌資策略、生產決策和合約保護的實際影響

2025年關稅和貿易措施的實施，為整個醫藥價值鏈的定價、供應鏈設計和籌資策略帶來了新的挑戰。關稅相關成本增加了原料藥和成品藥進口的難度，促使生產商重新評估其成本結構，並針對關稅、物流附加費和合規文件等因素進行情境規劃。因此，採購團隊和供應鏈高層優先考慮供應商多元化、盡可能選擇近岸外包以及更嚴格的庫存控制，以降低邊境相關的成本波動風險。

從綜合細分的觀點，明確了跨治療領域、藥物類別、給藥途徑、患者人口統計和分銷管道趨勢的臨床、製藥和分銷重點。

細分市場為理解不同臨床適應症、分子類別、給藥途徑、患者族群和通路的治療價值和商業性機會差異提供了一個切實可行的觀點。透過將腎上腺疾病、糖尿病、生長遲緩、骨質疏鬆症、腦下垂體疾病和甲狀腺疾病等治療領域與抑鈣素肽、生長激素、胰島素、口服降血糖藥、口服降血糖藥、副甲狀腺素及其類似物等藥物類別進行匹配，可以發現藥物研發複雜性、監管要求和患者依從性挑戰方面的關鍵模式。給藥途徑（吸入、注射、口服）的差異進一步影響產品定位，而給藥途徑相關的便利性和穩定性等因素則影響臨床應用和支付方的評估。

區域法規結構、支付方趨勢和基礎設施考慮因素將影響美洲、歐洲、中東和非洲以及亞太地區各區域的准入策略的製定方式。

區域趨勢對產品開發、監管規劃和商業化方面的策略決策有顯著影響。在美洲，成熟的支付方體系和完善的專科醫療路徑支持差異化治療方法的快速推廣，但報銷壓力和價格敏感性要求提供強力的衛生經濟學證據和結構完善的患者支持計劃。在這種環境下，能夠展現明確臨床效益、改善病患預後並能為醫療系統帶來顯著成本節約的產品更具優勢。

主要企業採取策略行動和業務投資，優先考慮產品線差異化、生產柔軟性和一體化患者准入解決方案。

產業相關人員正透過強調專業化、營運韌性和夥伴關係的策略措施來應對治療和商業壓力。主要企業正優先考慮透過內部創新和外部合作來實現產品線差異化，從而獲得互補能力，例如先進的製劑科學、生物製劑工程或數位化藥物合規平台。策略性授權和共同開發契約有助於分散開發風險、獲得當地監管的專業知識並縮短產品上市時間。

為產業領導者提供可操作的策略重點，以加強供應鏈韌性、提升與支付方的夥伴關係，並將數位化能力融入治療方案中。

產業領導企業應採取多管齊下的策略，在科學創新、實際應用和業務永續營運之間取得平衡。首先，他們應優先考慮供應鏈多元化，並制定短期緊急時應對計畫，以降低貿易相關成本衝擊帶來的風險。對於關鍵原料藥（API），他們應與多家供應商簽訂契約，並探索區域生產夥伴關係，以減少對特定地區的依賴。同時，他們應加快對製劑和給藥方式創新的投資，以提高用藥依從性，減輕給藥負擔，並擴大成人、老年人和兒童等不同患者群體的適用範圍。

嚴謹而多方面的研究途徑，結合專家訪談、監管審查、臨床證據整合和分段分析，檢驗了研究結果並指出了局限性。

本研究整合了透過與臨床醫生、保險公司、供應鏈經理和行業高管的專家訪談收集到的主要見解，並全面審查了監管指導文件、臨床文獻和公共公告。研究方法強調三角檢驗。將相關人員對話的見解與監管記錄、已發表的臨床試驗結果和營運資訊披露進行交叉比對，以檢驗結論反映了趨同的證據基礎。此外，還應用了細分映射，將治療適應症、藥物類別、給藥途徑、年齡層和分銷管道與臨床和商業性屬性相匹配。

它強調了整合知識、創造全面證據、加強供應鏈韌性以及促進相關人員，所有這些對於在治療方面取得進步都至關重要。

多種因素——包括治療方法創新、支付方預期變化以及貿易相關的成本壓力——要求研發、生產和商業部門協調應對。胜肽工程、生物製藥和遞送系統的進步為改善患者療效創造了新的機遇，但要充分發揮這些潛力，需要製定切實可行的策略，以確保治療的可負擔性、可及性和依從性。將循證實踐與以患者為中心的服務模式和穩健的供應鏈相結合的機構，將更有能力把臨床創新轉化為永續的醫療保健成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 內分泌藥物市場：依藥物類別分類

  • 抑鈣素肽
  • 生長激素
  • 胰島素
  • 口服降血糖藥
  • 口服降血糖藥
  • 副甲狀腺素及其類似物

第9章 內分泌藥物市場（依治療領域分類）

  • 腎上腺疾病
  • 糖尿病
  • 生長遲緩
  • 骨質疏鬆症
  • 腦下垂體疾病
  • 甲狀腺疾病

第10章 內分泌藥物市場（依給藥途徑分類）

  • 吸入劑
  • 注射藥物
  • 口服

第11章 依患者年齡層分類的內分泌藥物市場

  • 成人版
  • 老年人
  • 兒童

第12章 內分泌藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 內分泌藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 內分泌藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 內分泌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國內分泌藥物市場

第17章：中國內分泌藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Ascendis Pharma A/S
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici SpA
  • Eli Lilly and Company
  • Endo, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hanmi Pharm Co., Ltd.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • MacroGenics, Inc.
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Precigen, Inc.
  • Sanofi SA
  • Shenzhen Microchip Biotechnology Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market was valued at USD 65.43 billion in 2025 and is projected to grow to USD 70.12 billion in 2026, with a CAGR of 7.67%, reaching USD 109.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 65.43 billion
Estimated Year [2026] USD 70.12 billion
Forecast Year [2032] USD 109.78 billion
CAGR (%) 7.67%

An authoritative overview of how therapeutic innovation, regulatory shifts, and patient expectations are reshaping endocrinology drug strategies and care pathways

Endocrinology therapeutics occupy a central role in modern healthcare due to the chronic nature of many conditions, the ongoing innovation in biologics and small molecules, and evolving patient expectations for convenience and outcomes. Across clinical and commercial settings, stakeholders increasingly prioritize interventions that improve metabolic control, reduce complication rates, and support long-term adherence through improved formulations and delivery systems. Consequently, research that synthesizes therapeutic innovation, regulatory dynamics, and patient access trends is essential for clinicians, commercial leaders, and policy advisors who must balance clinical efficacy with real-world implementation challenges.

This executive summary frames the contemporary landscape by highlighting technological, regulatory, and supply chain developments that shape product strategy and patient care pathways. It contextualizes therapeutic progress in diabetes, thyroid, pituitary, and other endocrine conditions while emphasizing the importance of integrated approaches that combine pharmacology with digital health, patient support programs, and novel distribution models. Readers are guided to consider how innovation, payer priorities, and global trade dynamics converge to influence strategic planning and operational execution across the value chain.

How innovations in biologics, delivery systems, digital therapeutics, and regulatory frameworks are jointly redefining competitive strategies across endocrinology treatments

The endocrinology landscape is undergoing transformative shifts driven by advances in biologics, peptide engineering, and delivery technologies that enhance both efficacy and patient convenience. Novel GLP-1 receptor agonists and long-acting insulin analogs have catalyzed new standards of care, while improvements in formulation science enable less frequent dosing and alternative administration routes. Concurrently, digital health platforms and remote monitoring tools are integrating with therapeutic regimens to support adherence, titration, and personalized care plans, which in turn influence clinical trial design and post-market evidence generation.

Beyond therapeutics, commercial and regulatory frameworks are evolving to accommodate accelerated approvals, value-based contracting, and outcomes-based reimbursement. These trends incentivize robust real-world evidence programs and closer alignment between manufacturers, providers, and payers. Supply chain resilience and manufacturing flexibility have also become strategic priorities, prompting investments in regional production capabilities and partnerships that reduce lead times and improve responsiveness to demand fluctuations. Taken together, these shifts are creating an environment where therapeutic differentiation must be matched by excellence in commercialization and patient support.

Realistic implications of 2025 tariff measures on supply chains, sourcing strategies, manufacturing decisions, and contractual protections within the pharmaceutical ecosystem

The introduction of tariffs and trade measures in 2025 has introduced new considerations for pricing, supply chain design, and sourcing strategies across the pharmaceutical value chain. Tariff-related costs increase the complexity of importing active pharmaceutical ingredients and finished products, thereby prompting manufacturers to revisit cost structures and engage in scenario planning for customs duties, logistics surcharges, and compliance-related documentation. Consequently, procurement teams and supply chain executives have prioritized supplier diversification, nearshoring where feasible, and tighter inventory management to mitigate exposure to border-related cost volatility.

In parallel, regulatory authorities and commercial partners are responding to the changed trade environment by emphasizing transparency in cost pass-through and contractual protections that address tariff fluctuations. Research and development planning also reflects these dynamics; companies are exploring localized manufacturing for critical components, prioritizing modular production technologies that scale efficiently, and negotiating long-term agreements with suppliers to stabilize input costs. These pragmatic responses seek to preserve patient access and maintain continuity of care while adapting commercial models to a higher-cost trading environment.

Integrated segmentation perspectives that reveal clinical, formulation, and distribution priorities across therapy areas, drug classes, administration modes, demographics, and channel dynamics

Segmentation provides a practical lens for understanding how therapeutic value and commercial opportunity vary across clinical indications, molecule classes, modes of delivery, patient demographics, and distribution pathways. When therapy areas such as Adrenal Disorders, Diabetes, Growth Disorders, Osteoporosis, Pituitary Disorders, and Thyroid Disorders are juxtaposed with drug classes that include Calcitonin Peptides, Growth Hormone, Insulin, Oral Antidiabetics, Oral Hypoglycemics, and Parathyroid Hormones & Analogs, important patterns emerge in terms of development complexity, regulatory requirements, and patient adherence challenges. Mode of administration distinctions-Inhalable, Injectable, and Oral-further shape product positioning, with route-specific convenience and stability considerations influencing clinical adoption and payer evaluations.

Patient age group segmentation between Adult, Geriatric, and Pediatric populations also drives differentiated clinical trial design, safety monitoring, and formulation optimization, given varied pharmacokinetics and adherence behaviors across cohorts. Distribution channels that encompass Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies determine the commercial pathway for product launch and long-term access, affecting everything from cold chain logistics to patient counseling opportunities. Integrating these segmentation dimensions illuminates where therapeutic innovations are likely to achieve rapid uptake, where additional evidence or delivery innovation is necessary, and where patient support will be a decisive factor in sustained clinical and commercial success.

How regional regulatory frameworks, payer dynamics, and infrastructure considerations drive tailored access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence the strategic calculus for product development, regulatory planning, and commercialization. In the Americas, a mature payer ecosystem and established specialty care pathways support rapid adoption of differentiated therapies, although reimbursement pressure and price sensitivity require robust health economic evidence and well-structured patient support programs. This environment favors products that demonstrate clear clinical benefit and improved patient outcomes while delivering demonstrable cost offsets for healthcare systems.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement mechanisms necessitate tailored market entry strategies and flexible pricing approaches. Regional variation in infrastructure and access pathways means that manufacturers must design differentiated distribution and access programs that accommodate public healthcare procurement as well as private specialty channels. In the Asia-Pacific region, rapid adoption of new technologies and a growing emphasis on domestic manufacturing are notable trends. Diverse regulatory pathways and varying degrees of market maturity create opportunities for partnerships with local firms, co-development arrangements, and hybrid commercialization models that balance global expertise with local execution capabilities.

Strategic behaviors and operational investments by leading pharmaceutical companies that prioritize pipeline differentiation, manufacturing flexibility, and integrated patient access solutions

Industry actors are responding to therapeutic and commercial pressures with strategic moves that emphasize specialization, operational resilience, and partnership. Leading companies are prioritizing pipeline differentiation through both internal innovation and external alliances that deliver complementary capabilities, such as advanced formulation science, biologics engineering, or digital adherence platforms. Strategic licensing and co-development arrangements help accelerate time-to-market while distributing development risk and enabling access to local regulatory expertise.

Operationally, firms are investing in flexible manufacturing platforms, cold chain sophistication, and quality assurance processes that reduce supply disruptions and support international distribution. Commercial strategies increasingly incorporate outcomes-oriented contracting and integrated patient services to secure formulary positions and nurture long-term adherence. In parallel, mid-sized and specialty companies are carving out niches by delivering high-touch patient support and clinician education programs that complement therapeutic profiles and strengthen brand differentiation. Collectively, these behaviors reflect a sector-wide pivot toward integrated solutions that pair clinical value with pragmatic access mechanisms.

Practical strategic priorities for industry leaders to enhance supply chain resilience, strengthen payer partnerships, and integrate digital capabilities into therapeutic offerings

Industry leaders should adopt a multifaceted strategy that aligns scientific innovation with pragmatic access and operational resilience. First, prioritize supply chain diversification and near-term contingency planning to reduce exposure to trade-related cost shocks. Establish multi-sourcing agreements for critical APIs and consider regional production partnerships that lower dependency on single geographies. Simultaneously, accelerate investments in formulation and delivery innovations that improve adherence, reduce administration burden, and expand the addressable patient population across adult, geriatric, and pediatric cohorts.

Second, strengthen payer engagement through early health economic modelling and outcomes data collection to support value-based contracting. Develop real-world evidence programs and patient-reported outcomes initiatives that substantiate long-term benefits and inform pricing discussions. Third, cultivate partnerships that bring digital health capabilities into therapeutic offerings, enabling remote monitoring, adherence support, and personalized dosing regimens. Finally, embed regulatory foresight into R&D planning to leverage expedited pathways where appropriate and to design registrational programs that reflect post-market evidence requirements. Collectively, these actions will position organizations to deliver differentiated clinical value while managing commercial and operational risk.

A rigorous, multi-method research approach combining expert interviews, regulatory review, clinical evidence synthesis, and segmented analysis to validate insights and identify limitations

This research synthesizes primary insights gathered through expert interviews with clinicians, payers, supply chain managers, and industry executives alongside a thorough review of regulatory guidance documents, clinical literature, and public policy announcements. The methodological approach emphasizes triangulation: findings from stakeholder conversations were validated against regulatory records, published clinical trial results, and operational disclosures to ensure that conclusions reflect a convergent evidence base. Segmentation mapping was applied to align therapeutic indications, drug classes, modes of administration, age groups, and distribution channels with clinical and commercial attributes.

Quality control included cross-validation by domain experts, iterative refinement of themes, and sensitivity checks on supply chain and policy-related interpretations. Limitations stem from the evolving nature of trade measures and the lag between policy implementation and observable commercial impacts; where appropriate, the analysis distinguishes between documented changes and plausible near-term responses. Transparency about sources and methodological choices enables readers to assess the applicability of insights to their specific organizational contexts and to request bespoke deep dives focused on particular segments or geographies.

Consolidating insights to emphasize the imperative for integrated evidence generation, supply chain resilience, and stakeholder collaboration to realize therapeutic advances

The confluence of therapeutic innovation, changing payer expectations, and trade-related cost pressures requires a coordinated response across R&D, manufacturing, and commercial functions. Therapeutic advances in peptide engineering, biologics, and delivery systems are creating new opportunities for improved patient outcomes, yet realizing that potential depends on pragmatic strategies that ensure affordability, access, and adherence. Organizations that integrate evidence generation with patient-centric service models and resilient supply chains will be best positioned to convert clinical innovation into sustained health impact.

Looking ahead, continued collaboration among manufacturers, providers, payers, and regulators will be essential to navigate evolving reimbursement paradigms and to respond to geopolitical influences on trade. Strategic investments in regional manufacturing, digital health integration, and real-world evidence capabilities will provide durable advantages. Ultimately, success will hinge on the ability to combine scientific excellence with operational adaptability and stakeholder alignment so that therapeutic advances translate into measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endocrinology Drugs Market, by Drug Class

  • 8.1. Calcitonin Peptides
  • 8.2. Growth Hormone
  • 8.3. Insulin
  • 8.4. Oral Antidiabetics
  • 8.5. Oral Hypoglycemics
  • 8.6. Parathyroid Hormones & Analogs

9. Endocrinology Drugs Market, by Therapy Area

  • 9.1. Adrenal Disorders
  • 9.2. Diabetes
  • 9.3. Growth Disorders
  • 9.4. Osteoporosis
  • 9.5. Pituitary Disorders
  • 9.6. Thyroid Disorders

10. Endocrinology Drugs Market, by Mode of Administration

  • 10.1. Inhalable
  • 10.2. Injectable
  • 10.3. Oral

11. Endocrinology Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Endocrinology Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Endocrinology Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endocrinology Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endocrinology Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Endocrinology Drugs Market

17. China Endocrinology Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Ascendis Pharma A/S
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Biocon Limited
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. CHIESI Farmaceutici S.p.A.
  • 18.14. Eli Lilly and Company
  • 18.15. Endo, Inc.
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. GlaxoSmithKline PLC
  • 18.18. Hanmi Pharm Co., Ltd.
  • 18.19. Ipsen Pharma
  • 18.20. Johnson & Johnson Services, Inc.
  • 18.21. MacroGenics, Inc.
  • 18.22. MannKind Corporation
  • 18.23. Merck & Co., Inc.
  • 18.24. Novartis AG
  • 18.25. Novo Nordisk A/S
  • 18.26. Oramed Pharmaceuticals Inc.
  • 18.27. Pfizer Inc.
  • 18.28. Precigen, Inc.
  • 18.29. Sanofi S.A
  • 18.30. Shenzhen Microchip Biotechnology Co., Ltd.
  • 18.31. Sun Pharmaceutical Industries Limited
  • 18.32. Takeda Pharmaceutical Company Limited
  • 18.33. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)